This abstract will be presented at a press conference, “Late Breaking Clinical Trials,” hosted by AACR President-elect Charles L. Sawyers, M.D., chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, at 1 p.m. ET on April 6 in Room 153 of the Walter E. Washington Convention Center. Reporters who cannot attend in person can call in using the following information:• U.S./Canada (toll free): 1 (800) 446-2782• International (toll call): 1 (847) 413-3235

Newswise — WASHINGTON, D.C. — A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

“This immunotherapeutic strategy has two steps — dendritic cell vaccination and adoptive T-cell therapy. This is the first time such a combination immunotherapy approach has been used for patients with ovarian cancer,” said Lana Kandalaft, Pharm.D., M.T.R., Ph.D., assistant professor and director of clinical development and operations at the Ovarian Cancer Research Center in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. “Most patients with ovarian cancer are diagnosed at an advanced stage and many of those relapse within two years; most die within five years. Given these grim outcomes, there is definitely a vast unmet need for the development of novel, alternate therapies.”

According to Kandalaft, the first step of the immunotherapy approach is to preserve the patient’s tumor at the time of surgery so it can be used to manufacture a personalized vaccine that teaches the patient’s own immune system to attack the tumor.

For this protocol, Kandalaft and colleagues isolated immune cells called dendritic cells from the blood of 31 patients with recurrent, progressive, stage 3 and 4 ovarian cancer. They then prepared the vaccine by exposing each patient’s dendritic cells to her own tumor tissue that had been collected during surgery. The first six patients were assigned to the first version of a vaccine while the other 25 were assigned to an enhanced vaccine with an optimized platform developed at the Penn Ovarian Cancer Research Center.

Nineteen of these patients showed clinical benefit after vaccine treatment and developed an antitumor immune response. Of these 19 patients, eight had no measurable disease at the end of the study and remained on maintenance vaccine therapy. One patient of the eight patients remained disease-free for 42 months following vaccine treatment.

Eleven patients who responded to the vaccine treatment but still had residual disease moved to the second step of the immunotherapy: adoptive T-cell therapy. At this point, the researchers removed immune cells called T cells from patients’ blood, stimulated and expanded the cells in the laboratory, and then reinjected them into the patients. The team found that because the T cells had already been educated by the dendritic cell vaccine to attack the tumor cells, the adoptive T-cell transfer amplified the antitumor immune response. Of these 11 patients, seven had stable disease and one had a complete response.

While vaccination therapy alone showed about a 61 percent clinical benefit, the combination of both therapies showed about a 75 percent benefit, according to Kandalaft. “We offer patients with ovarian cancer a potential therapy with minor side effects and a good quality of life,” she said. The team continues to work to improve the vaccine platform to further enhance its efficacy.

Both treatments were given in conjunction with bevacizumab, a drug that controls blood vessel growth. Combining bevacizumab with immunotherapy makes a powerful duo, according to Kandalaft. Currently, the vaccine trial is still open to accrual to test new combinatorial strategies.

This study was funded by a National Cancer Institute Ovarian Specialized Program of Research Excellence grant, the National Institutes of Health and the Ovarian Cancer Immunotherapy Initiative.

# # #

Press registration for the AACR Annual Meeting 2013 is free to qualified journalists and public information officers: www.aacr.org/PressRegistration.

Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org

About the American Association for Cancer ResearchFounded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

Abstract Number: LB-335

Presenter: Lana Kandalaft, Pharm.D., M.T.R., Ph.D.

Title: Autologous Whole-Tumor Antigen Vaccination in combination with Adoptive T cell Therapy for Patients with Recurrent Ovarian Cancer

Authors: Lana E. Kandalaft, Janos Tanyi, Cheryl Chiang, Daniel Powell, George Coukos. University of Pennsylvania, Philadelphia, PA

Novel therapeutic strategies are warranted in recurrent ovarian cancer. We report two independent consecutive studies of combinatorial immunotherapy comprising dendritic cell (DC)-based autologous whole tumor antigen vaccination in combination with antiangiogenesis therapy. 31 patients with recurrent progressive stage III and IV ovarian cancer with available tumor lysate from secondary debulking surgery enrolled in two different studies. First 6 underwent priming with intravenous bevacizumab and oral metronomic cyclophosphamide followed by vaccination with an autologous DC preparation pulsed with freeze-thaw autologous tumor lysate while the other 25 underwent vaccination with an enhanced vaccine where autologous DCs were loaded with HOCl-oxidized autologous tumor lysate administered intranodally every 2 weeks in combination with intravenous bevacizumab. Both studies were followed by lymphodepletion and transfer of autologous vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood T-cells, in combination with antiangiogenesis therapy and vaccination. Feasibility, safety, and biological and clinical efficacy were evaluated. Eleven subjects have completed vaccination and T cell transfer to date, while twenty-three additional subjects completed vaccination only. Vaccination was well tolerated and elicited tumor-specific T cell responses against various ovarian tumor antigen in both studies and clinical benefit of 65% correlated with the immune response with some experiencing prolonged progression free survival. Following lymphodepletion, adoptive transfer of vaccine-primed T-cells was well tolerated and resulted in durable reduction of T-regulatory cells and restoration of vaccine-induced antitumor immunity in patients who experienced clinical benefit. One patient exhibited no evidence of disease at end of study. Stable disease was observed in 8 subjects to date. Data on additional patients will be presented at the meeting. Our results suggest the use of combinatorial cellular immunotherapy comprising DC vaccination with whole tumor antigen and adoptive lymphocyte transfer using tumor antigen-specific T cells for the treatment of patients with recurrent ovarian cancer is promising yet warrants further investigation.

MEDIA CONTACT
Register for reporter access to contact details
CITATIONS

American Association for Cancer Research Annual Meeting 2013